Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to 0.04%.

  • Xeris Biopharma Holdings' Return on Capital Employed rose 23.00% to 0.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.04%, marking a year-over-year increase of 23.00%. This contributed to the annual value of -0.15% for FY2024, which is 3.00% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Return on Capital Employed stood at 0.04%, which was up 197.12% from -0.04% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Return on Capital Employed registered a high of 0.04% during Q3 2025, and its lowest value of -0.83% during Q4 2021.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.18% (2024), whereas its average is -0.15%.
  • Data for Xeris Biopharma Holdings' Return on Capital Employed shows a peak YoY spiked of 50bps (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Return on Capital Employed stood at -0.83% in 2021, then skyrocketed by 50bps to -0.33% in 2022, then rose by 14bps to -0.19% in 2023, then rose by 4bps to -0.15% in 2024, then increased by 23bps to 0.04% in 2025.
  • Its Return on Capital Employed stands at 0.04% for Q3 2025, versus -0.04% for Q2 2025 and -0.10% for Q1 2025.